Clin Chem Lab Med. 2015 May;53(6):887-91. doi: 10.1515/cclm-2014-1201.
The organizers of the first EFLM Strategic Conference "Defining analytical performance goals" identified three models for defining analytical performance goals in laboratory medicine. Whereas the highest level of model 1 (outcome studies) is difficult to implement, the other levels are more or less based on subjective opinions of experts, with models 2 (based on biological variation) and 3 (defined by the state-of-the-art) being more objective. A working group of the German Society of Clinical Chemistry and Laboratory Medicine (DGKL) proposes a combination of models 2 and 3 to overcome some disadvantages inherent to both models. In the new model, the permissible imprecision is not defined as a constant proportion of biological variation but by a non-linear relationship between permissible analytical and biological variation. Furthermore, the permissible imprecision is referred to the target quantity value. The biological variation is derived from the reference interval, if appropriate, after logarithmic transformation of the reference limits.
第一届 EFLM 战略会议“定义分析性能目标”的组织者确定了三种用于定义实验室医学中分析性能目标的模型。虽然模型 1(结果研究)的最高级别难以实施,但其他级别或多或少基于专家的主观意见,模型 2(基于生物学变异)和模型 3(由最先进技术定义)更具客观性。德国临床化学和实验室医学学会(DGKL)的一个工作组提出将模型 2 和模型 3 相结合,以克服这两种模型固有的一些缺点。在新模型中,允许的不精密度不是定义为生物学变异的恒定比例,而是允许的分析和生物学变异之间的非线性关系。此外,允许的不精密度是相对于目标数量值的。生物学变异是从参考区间得出的,如果合适的话,在参考限对数转换后。